NAMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NewAmsterdam Pharma (NAMS) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are potential catalysts in the future, such as the mid-2026 PREVAIL trial update and a 2027 launch, the current technical indicators, insider selling trends, and weak financial performance suggest that it is better to wait for more clarity or a stronger entry point.
The MACD is negative and expanding (-0.282), indicating bearish momentum. RSI is neutral at 31.716, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 31.837) with resistance at 33.911. Overall, the technical indicators suggest a weak or neutral trend.
Analysts are optimistic about the company's lead asset, obicetrapib, with positive Phase 3 data and potential near-term inflection points like the PREVAIL trial update and 2027 launch. Price targets from analysts are significantly above the current price, with Truist at $57 and Guggenheim at $45.
Insiders are selling shares, with a 113.69% increase in selling activity over the last month. Additionally, the financial performance in Q3 2025 shows a significant revenue drop (-98.80% YoY) and continued net losses (-$72M). No recent news or congress trading data to support bullish sentiment.
In Q3 2025, revenue dropped by 98.80% YoY to $348,000. Net income improved but remains negative at -$72M (+332.54% YoY). EPS increased to -0.61 (+238.89% YoY), and gross margin remains at 100%. Overall, the financials indicate a struggling company with no immediate signs of recovery.
Analysts maintain a Buy rating with high price targets ($45-$57). They are optimistic about the company's long-term potential, particularly the PREVAIL trial update and the 2027 launch of obicetrapib. However, these catalysts are mid- to long-term and do not address current bearish trends.
